Q-omics provides the consensus-scored ALDH1L2 profile across patient tissues and cancer cell-line models. ALDH1L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ALDH1L2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ALDH1L2 protein abundance shows 21,224 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where ALDH1L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH1L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH1L2 survival associations across molecular data types. ALDH1L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH1L2 RNA expression–survival associations across cancer types. High ALDH1L2 expression shows unfavorable associations in KIRP, BLCA, STAD, UVM, ACC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ALDH1L2 RNA expression.
This table summarizes ALDH1L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ALDH1L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH1L2 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LUAD, LUSC and KIRP. The HNSC box plot shows higher ALDH1L2 RNA expression in tumor versus normal tissue (log2 FC = +1.486, t-test p < 0.001).
This table shows molecular features associated with ALDH1L2 in patient tissues and cancer cell lines. In patient samples, ALDH1L2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ALDH1L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
